Literature DB >> 22197027

(18)FDG-PET/CT for detection of mediastinal nodal metastasis in non-small cell lung cancer: a meta-analysis.

Lin Zhao1, Zhi-Yi He, Xiao-Ning Zhong, Miao-Ling Cui.   

Abstract

BACKGROUND: We performed a meta-analysis to evaluate the role of (18)F-fluorodeoxyglucos -e positron emission tomography/computed tomography ((18)FDG-PET/CT) in detecting mediastinal nodal metastasis in patients with non-small cell lung cancer (NSCLC).
METHODS: Studies about (18)FDG-PET/CT for detecting mediastinal nodal metastasis in patient with NSCLC were systematically searched in the MEDLINE, EMBASE, and EBM Review databases from January 1, 2000 to July 26, 2011. A software called "Meta-Disc" was used to obtain pooled estimates of sensitivity, specificity, positive likelihood ratio (PLR), and negative likelihood ratio (NLR), respectively. We also calculated summary receiver operating characteristic (SROC) curves, and the Q* index.
RESULTS: 20 articles fulfilled all inclusion criteria (3028 eligible patients). The pooled sensitivity, and specificity with 95% confidence interval for PET/CT on a per-patient analysis were 0.719 (0.683-0.753), and 0.898 (0.882-0.912). Corresponding values for PET/CT on a per-nodal-station analysis were 0.610 (0.582-0.636), 0.924 (0.918-0.930). The Q* index estimates under SROC were 0.8464 and 0.8067, respectively.
CONCLUSIONS: (18)FDG-PET/CT had more specificity but less sensitivity for mediastinal nodal metastasis in patients with NSCLC.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22197027     DOI: 10.1016/j.suronc.2011.11.001

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  11 in total

1.  Multidisciplinary consensus statement on the clinical management of patients with stage III non-small cell lung cancer.

Authors:  M Majem; J Hernández-Hernández; F Hernando-Trancho; N Rodríguez de Dios; A Sotoca; J C Trujillo-Reyes; I Vollmer; R Delgado-Bolton; M Provencio
Journal:  Clin Transl Oncol       Date:  2019-06-06       Impact factor: 3.405

2.  Can CT radiomics differentiate benign from malignant N2 adenopathy in non-small cell lung cancer.

Authors:  Robert J Cerfolio; William H Moore
Journal:  Transl Lung Cancer Res       Date:  2020-10

Review 3.  Present and future roles of FDG-PET/CT imaging in the management of lung cancer.

Authors:  Kazuhiro Kitajima; Hiroshi Doi; Tomonori Kanda; Tomohiko Yamane; Tetsuya Tsujikawa; Hayato Kaida; Yukihisa Tamaki; Kozo Kuribayashi
Journal:  Jpn J Radiol       Date:  2016-04-27       Impact factor: 2.374

Review 4.  Current role of standardized uptake valuemax-derived ratios in N2 fluorine-18 fluorodeoxyglucose positron-emission tomography non-small cell lung cancer.

Authors:  Duilio Divisi; Mirko Barone; Roberto Crisci
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

5.  Prognostic value of volumetric parameters of (18)F-FDG PET in non-small-cell lung cancer: a meta-analysis.

Authors:  Hyung-Jun Im; Kyoungjune Pak; Gi Jeong Cheon; Keon Wook Kang; Seong-Jang Kim; In-Joo Kim; June-Key Chung; E Edmund Kim; Dong Soo Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-09-06       Impact factor: 9.236

Review 6.  Advances in multimodal treatment for stage IIIA-N2 non-small cell lung cancer.

Authors:  Sara Montemuiño Muñiz; Soraya Marcos Sánchez; Julia Calzas Rodríguez; Beatriz Losada Vila; Esther Llorente Herrero; María Dolores Hisado Díaz; Victoria Valeri-Busto González; Begoña Taboada Valladares; Blanca Vaquero Barrón; Francisco José Marcos Jimenez; Sergio Amor Alonso; Javier Moradiellos; Núria Rodríguez de Dios; Felipe Couñago
Journal:  J Clin Transl Res       Date:  2021-04-16

7.  Application of Artificial Neural Network to Preoperative 18F-FDG PET/CT for Predicting Pathological Nodal Involvement in Non-small-cell Lung Cancer Patients.

Authors:  Silvia Taralli; Valentina Scolozzi; Luca Boldrini; Jacopo Lenkowicz; Armando Pelliccioni; Margherita Lorusso; Ola Attieh; Sara Ricciardi; Francesco Carleo; Giuseppe Cardillo; Maria Lucia Calcagni
Journal:  Front Med (Lausanne)       Date:  2021-04-22

8.  Implications of false negative and false positive diagnosis in lymph node staging of NSCLC by means of ¹⁸F-FDG PET/CT.

Authors:  Shaolei Li; Qingfeng Zheng; Yuanyuan Ma; Yuzhao Wang; Yuan Feng; Bingtian Zhao; Yue Yang
Journal:  PLoS One       Date:  2013-10-25       Impact factor: 3.240

9.  Use quantitative parameters in spectral computed tomography for the differential diagnosis of metastatic mediastinal lymph nodes in lung cancer patients.

Authors:  Suidan Huang; Hongjia Meng; Renli Cen; Zhiwen Ni; Xiaoling Li; Sushant Suwal; Huai Chen
Journal:  J Thorac Dis       Date:  2021-08       Impact factor: 2.895

10.  Identification of false-negative and false-positive diagnoses of lymph node metastases in non-small cell lung cancer patients staged by integrated (18F-)fluorodeoxyglucose-positron emission tomography/computed tomography: A retrospective cohort study.

Authors:  Kaoru Kaseda; Ken-Ichi Watanabe; Keisuke Asakura; Akio Kazama; Yukihiko Ozawa
Journal:  Thorac Cancer       Date:  2016-05-05       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.